Long-Term Investment or Short-Term? Las Vegas Sands Corp. (LVS), Eyegate Pharmaceuticals, Inc. (EYEG)

The shares of Las Vegas Sands Corp. (NYSE:LVS) and Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) were among the active stocks of the last trading sessions. Las Vegas Sands Corp. (NYSE:LVS) declined to -0.05% closing at the price of $58.28 whereas the shares of Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) soared 7.96% with the increase of 0.03 points closing at the price of $0.42. Las Vegas Sands Corp. has currently decrease -17.74% in its stock over the period of 6-months while its rival Eyegate Pharmaceuticals, Inc. added 1.43% in the previous 6-months.

Now we have to analyze the facts that if the stocks were worthy off investors’ money? The facts to analyze here are risks, profitability, returns and price trends.

Returns and Profitability

Profitability and returns are the main reason of investment, the investors are looking for profits that they get and return they should expect over the period of time.

The first and foremost return that is considered while making an investment is the ROI or Return on Investment. The ROI is the ratio between the profit against the cost of investment. Currently the ROI of Las Vegas Sands Corp. (NYSE:LVS) is 19.5% while the ROI of Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) is 695.6%. Another figure that is to be considered while analyzing the profitability of a share is its EBITDA margin, LVS’s EBITDA Margin is 10.7 whereas EYEG’s is -0.32.

Both the profitability ratios suggest a mixed sentiment for Las Vegas Sands Corp. (NYSE:LVS) and Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG).

EPS & Surprise Factor

Las Vegas Sands Corp. (NYSE:LVS) reported $0.74/share EPS for the previous quarter where analysts were predicting an EPS to be $0.79/share Thus lagging the analyst Estimates with a Surprise Factor of -6.3 Percent. While, Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) reported EPS of $-0.07/share in the last quarter. The analysts projected EPS of $-0.14/share depicting a Surprise of 50 Percent.

Taking a look at Earnings per Share, Eyegate Pharmaceuticals, Inc. tends to be beating the analyst estimates more than Las Vegas Sands Corp.. so EYEG is more profitable than LVS.

Technical Analysis of Las Vegas Sands Corp. & Eyegate Pharmaceuticals, Inc.

Moving average convergence divergence (MACD) shows that Las Vegas Sands Corp. (NYSE:LVS) is on a PRICE RELATIVITY trend While Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) is on PRICE RELATIVITY trend. The trend for the past 10-days shows that the Las Vegas Sands Corp. was in BEARISH territory and Eyegate Pharmaceuticals, Inc. was in BULLISH territory.

LVS’s current statistics gauge that the stock candle is BEARISH with MEDIUM volatility. While EYEG’s candle is BULLISH with HIGH.

EPS Growth Rate: LVS’s 7.01% versus EYEG’s 0%

Another shareholder value can be analyzed through the EPS growth rate; the next 5 years EPS growth rate is predicted by the analysts after the analyzing the previous trends. The next 5 year EPS growth rate of Las Vegas Sands Corp. (NYSE:LVS) is predicted at 7.01% while Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) stands at 0%. These numbers suggest that LVS is more suitable investment in terms of EPS growth rate.

Financial Risk and Liquidity Concerns

The current ratio and the debt ratio are the two ratios that show the investor how quickly the company is able to payout its debt and how quickly it can cover its obligations. The current ratio of LVS stands at 1.7 while EYEG is at 3.2 whereas the debt ratio of the prior is 1.58 while the debt ratio of the later is 0.

The values of the both ratios suggest that one is more liquid and other investment is more risk free.

Analyst Recommendations

While making an investment, another main factor to consider before investing is the analyst recommendation on the scale of 1 to 5 where 1 is strong buy, 2 is buy, 3 is hold, 4 is Sell and 5 is strong sell. Analyst recommend 2.4 for LVS and 2 for EYEG which means LVS has Hold rating whereas EYEG has Buy rating.

Another recommendation of analyst that is to be considered worthy is the price target. The mare price or price trend does not suggest the suitability of a stock. The price target set by analyst is also to be considered while investing as it suggests to what extent the stock will rise or fall in the near future. The price target set for LVS is $79.44 which is 26.64% of its current price while EYEG has price target of 3 which is 86% of its current price.

Valuation Ratios

Valuation is the process of determining the company’s worth for an investor, the valuation ratios give an insight to that worthiness.

LVS currently has price to earning P/E ratio of 14.11 whereas EYEG has 0 while the forward P/E ratio for the prior stands at 16.06 and for the later it depicts the value of 20.95.

The price to Book P/B for LVS is 6.43, Price to Sale is at 3.44 and for EYEG these ratios stand at 1.16 and 14.49.